Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Operating Leases (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Operating Leases for 2 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 19.31% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 19.31% year-over-year, with the annual reading at $5.6 million for FY2025, 19.31% down from the prior year.
  • Operating Leases hit $5.6 million in Q4 2025 for Xilio Therapeutics, down from $6.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $7.9 million in Q1 2024 to a low of $5.6 million in Q4 2025.